Lexicon Pharmaceuticals (LXRX) : The most positive equity analysts on Lexicon Pharmaceuticals (LXRX) expects the shares to touch $31, whereas, the least positive believes that the stock will trade at $11 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $22.5 with an expected fluctuation of $10.69 from the mean.
Lexicon Pharmaceuticals (LXRX) has an average broker rating of 2.4, which is interpreted as a Buy, as rated by 5 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.
Also, Major Brokerage house, Stifel Nicolaus maintains its ratings on Lexicon Pharmaceuticals (NASDAQ:LXRX). In the latest research report, Stifel Nicolaus raises the target price from $25 per share to $26 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 5, 2016.
Lexicon Pharmaceuticals (NASDAQ:LXRX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.85 and $13.80 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $14.37. The buying momentum continued till the end and the stock did not give up its gains. It closed at $14.33, notching a gain of 3.24% for the day. The total traded volume was 484,474 . The stock had closed at $13.88 on the previous day.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Companys telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Companys sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.